Daniel G. Chong

Glucagon-Like Peptide 1 Recruits Microvasculature and Increases Glucose Use in Muscle via a Nitric Oxide–Dependent Mechanism

Graft microvascular disease in solid organ transplantation

LinkedOmics: analyzing multi-omics data within and across 32 cancer types

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Microvascular dysfunction: An emerging pathway in the pathogenesis of obesity-related insulin resistance

The JAK/STAT signaling pathway: from bench to clinic

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Investigational Janus kinase inhibitors

Short-chain fatty acids in control of body weight and insulin sensitivity

Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma

Cancer-related inflammation and treatment effectiveness

Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance

Breaking up of prolonged sitting over three days sustains, but does not enhance, lowering of postprandial plasma glucose and insulin in overweight and obese adults

JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Benefits for Type 2 Diabetes of Interrupting Prolonged Sitting With Brief Bouts of Light Walking or Simple Resistance Activities

New mutations and pathogenesis of myeloproliferative neoplasms

Natural product and natural product derived drugs in clinical trials

Physical Activity/Exercise and Diabetes: A Position Statement of the American Diabetes Association

Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia

Muscle Contraction, but Not Insulin, Increases Microvascular Blood Volume in the Presence of Free Fatty Acid–Induced Insulin Resistance

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1